Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortality at acceptable costs. However, compared to nearly all other CRC screening strategies reimbursed by CMS it is less effective and considerably more costly, making it an inefficient screening option.